Equities

Ocumension Therapeutics

Ocumension Therapeutics

Actions
  • Price (USD)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,0541,3141,785
Total Receivables, Net11911344
Total Inventory32244.99
Prepaid expenses------
Other current assets, total03.90--
Total current assets1,2061,4551,835
Property, plant & equipment, net468448366
Goodwill, net------
Intangibles, net1,140919710
Long term investments36495272
Note receivable - long term------
Other long term assets93126148
Total assets3,2713,0443,331
LIABILITIES
Accounts payable25224.41
Accrued expenses251511
Notes payable/short-term debt12000
Current portion long-term debt/capital leases12124.19
Other current liabilities, total133199196
Total current liabilities315248216
Total long term debt5.66177.03
Total debt1383011
Deferred income tax------
Minority interest------
Other liabilities, total3030--
Total liabilities351295223
SHAREHOLDERS EQUITY
Common stock0.050.050.05
Additional paid-in capital7,6267,4287,355
Retained earnings (accumulated deficit)(5303)(5028)(4626)
Treasury stock - common0.000.000.00
Unrealized gain (loss)155(178)(0.31)
Other equity, total------
Total equity2,9202,7493,108
Total liabilities & shareholders' equity3,2713,0443,331
Total common shares outstanding691689667
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.